OptiBiotix Health PLC Exercise of Warrants and Issue of Equity (3307W)
08 February 2017 - 9:30AM
UK Regulatory
TIDMOPTI
RNS Number : 3307W
OptiBiotix Health PLC
08 February 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Exercise of Warrants and Issue of Equity
OptiBiotix Health plc (AIM: OPTI), a Life Sciences business
developing compounds to tackle obesity, high cholesterol and
diabetes announces that the Company has received notification from
warrant holders to exercise warrants over 16,351 ordinary shares of
2p each in the Company at an exercise price of 8p per share,
providing the Company with gross proceeds of GBP1,308.
Application will be made to the London Stock Exchange to admit
the 16,351 new ordinary shares to trading on AIM. Admission of the
new ordinary shares is expected to occur on or around 13 February
2017. The new ordinary shares will rank pari passu with the
existing ordinary shares.
For the purpose of the Disclosure and Transparency Rules,
following the issue of shares detailed above the enlarged issued
share capital of the Company will comprise 78,543,318 ordinary
shares of 2p each. The above figure may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the Company, under the Disclosure and
Transparency Rules.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Contact via Walbrook below
Executive
Cairn Financial Advisers Tel: 020 7148 7900
LLP
Liam Murray / Tony Rawlinson
Hybridan LLP (Joint Broker)
Claire Louise Noyce Tel: 020 3764 2341
Peterhouse Corporate Finance Tel: 020 7469 0936
Ltd (Joint Broker)
Lucy Williams / Duncan
Vasey
Walbrook PR Ltd Tel: 020 7933 8780 or
optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
Mike Wort Mob: 07900 608 002
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEUGUGPPUPMUBR
(END) Dow Jones Newswires
February 08, 2017 04:30 ET (09:30 GMT)